<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36730755</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3724</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine</Title><ISOAbbreviation>Clin J Sport Med</ISOAbbreviation></Journal><ArticleTitle>Patient-Centered Paradigm for Managing Autonomic Long COVID Symptoms During Sports and Exercise.</ArticleTitle><Pagination><StartPage>e14</StartPage><EndPage>e15</EndPage><MedlinePgn>e14-e15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JSM.0000000000001093</ELocationID><Abstract><AbstractText>This report highlights a new, patient-centered paradigm for managing post-COVID-19 dysautonomia symptoms during sports and exercise. The patient was a healthcare worker exposed before vaccination. She experienced postural orthostatic tachycardia plus exertional tachycardia, with postexertional fatigue, beginning a few weeks after testing positive for COVID-19. Stress test, echo, and an extensive dysautonomia evaluation were negative. Recommended nonpharmacological and pharmacological interventions were poorly tolerated. Prescription of a novel regimen of "basal-dose" ivabradine, plus very low-dose metoprolol according to an exertional "sliding scale" managed symptoms to an acceptable level for work and recreation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Messinger-Rapport</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0818-7693</Identifier><AffiliationInfo><Affiliation>Oak Street Health, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grubb</LastName><ForeName>Blair</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Toledo Medical Center, Toledo, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin J Sport Med</MedlineTA><NlmUniqueID>9103300</NlmUniqueID><ISSNLinking>1050-642X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054969" MajorTopicYN="Y">Primary Dysautonomias</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013610" MajorTopicYN="N">Tachycardia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054972" MajorTopicYN="Y">Postural Orthostatic Tachycardia Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36730755</ArticleId><ArticleId IdType="doi">10.1097/JSM.0000000000001093</ArticleId><ArticleId IdType="pii">00042752-202303000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13:943&#x2013;950.</Citation></Reference><Reference><Citation>Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34:750&#x2013;755.</Citation></Reference><Reference><Citation>Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting&#x2014;part 1. Auton Neurosci. 2021;235:102828.</Citation></Reference><Reference><Citation>O'Sullivan JS, Lyne A, Vaughan CJ. COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine. BMJ Case Rep. 2021:14:e243585.</Citation></Reference><Reference><Citation>Parker WH, Moudgil R, Wilson RG, et al. COVID-19 and postural tachycardia syndrome: a case series. Eur Heart J Case Rep. 2021;5:ytab325.</Citation></Reference><Reference><Citation>Tahir F, Bin Arif T, Majid Z, et al. Ivabradine in postural orthostatic tachycardia syndrome: a review of the literature. Cureus. 2020;12:e7868.</Citation></Reference><Reference><Citation>Martin RIR, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506&#x2013;1510.</Citation></Reference><Reference><Citation>Gibson DG. Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man. Drugs. 1974;7:8&#x2013;38.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>